Acute Kidney Injury in Coronavirus Disease-19 (COVID-19) Patients Admitted to the Intensive Care Unit (ICU)

The aim of this study is to evaluate the rate and outcomes of COVID-19 associated acute
kidney injury (AKI) and use of kidney replacement therapy (KRT) in critically ill COVID-19
patients in ICUs in several large hospitals in Flanders, the northern region of Belgium. We
will also explore the associations between several baseline risk factors for AKI, therapeutic
strategies and COVID-19 related clinical signs and the occurrence of AKI and use of KRT.

This will be a cohort analysis of the rate of COVID-19 associated AKI and KRT during the
period 1 February 2020 - 31 January 2021 in 6 large hospitals in Flanders Belgium and 3
Flemish University Hospitals. We will collect patients' baseline characteristics, specific
treatment for COVID-19, other relevant therapies and severity of illness and ICU and hospital
outcome data. AKI will be assessed during ICU stay up to 21 days of ICU stay, and will be
defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition. In
addition, we will assess occurrence of AKI stages, duration of AKI, duration of AKI
integrated with severity stage of AKI into the area under the curve of AKI, occurrence of
rapid reversal of AKI, occurrence of Acute Kidney Disease (AKD) defined according to KDIGO.